ABSTRACT: Introduction: Myasthenia gravis (MG) is a neuromuscular junction (NMJ) disorder caused by autoantibodies against NMJ proteins. Collagen XIII is a muscle-derived transmembrane protein required for NMJ maturation. The objective of this study was to assess for the presence of autoantibodies to collagen XIII in MG patients. Methods: Seventy MG patient sera and 61 human healthy controls were screened for collagen XIII autoantibodies by enzyme-linked immunosorbent assay. The collagen XIII autoantibody-positive sera were further analyzed by a cell-based assay together with Western blotting and immunofluorescence staining of cells expressing recombinant collagen XIII. Results: Five of the 70 MG patients were found to have autoantibodies against collagen XIII. All 5 patients were young women with no or low levels of autoantibodies to acetylcholine receptor. Discussion: Collagen XIII is associated with MG, but it is unknown whether the collagen XIII autoantibodies are pathogenic.
Muscle Nerve 57: [506] [507] [508] [509] [510] 2018 Myasthenia gravis (MG) is an autoimmune disease caused mainly by antibodies to the neuromuscular junction (NMJ) components. 1, 2 These antibodies influence neuromuscular transmission by 3 mechanisms: they damage the postsynaptic membrane with the help of complement 3 ; they cause antigenic modulation resulting in NMJ protein endocytosis 4 ; and, more rarely, they directly block the effect of acetylcholine. 5 These effects lead to weakness and fatigue in skeletal muscles. Autoimmune antibodies against muscle acetylcholine receptor (AChR) are detected in 80%-90% of MG patients. 6 In the remaining patients, 50% have autoantibodies to muscle-specific kinase (MuSK), lipoprotein-related protein 4 (LRP4), agrin, titin, or ryanodine receptor (RyR). [7] [8] [9] [10] [11] A small number Collagen XIII is a member of a collagen subgroup termed MACITs (membrane-associated collagens with interrupted triple helices), composed of a short cytosolic domain, a single transmembrane domain, and a largely collagen ectodomain. [12] [13] [14] The ectodomain can become proteolytically shed and it has been shown to interact with other extracellular matrix (ECM) molecules. 15 Genetically engineered mouse models have suggested requirements for collagen XIII in the maturation of NMJ. 16 Mutations in COL13A1 cause congenital myasthenic syndrome (CMS) type 19, showing ptosis, limb hypotonia, neck and bulbar weakness, and dysmorphic features. 17 The objective of this study was to identify autoimmune antibodies against collagen XIII in unselected MG patients.
METHODS
Seventy MG patients were recruited consecutively at Karolinska University Hospital, Solna, Sweden. Six patients had their blood samples collected twice after the onset of MG, and 2 patients had 3 blood samples. The MG diagnosis was based on abnormal muscle fatigability tests according to the International Classification of Diseases (ICD) code ICD-10:G70.0 and a decrement on 3-HZ repetitive nerve stimulation. AChR antibodies and human leukocyte antigens (HLA) were tested. 6, 18 Nineteen of 70 patients were AChR antibody seronegative. Written informed consent was obtained from all participants, and the study was approved by the hospital's ethics committee. Sera from 61 controls were collected at Oulu University Hospital, Finland. These individuals did not have MG symptoms defined in ICD-10 code G70.0, thyroid-associated ophthalmopathy, multiple sclerosis, rheumatoid arthritis, or cancer. They were age-and gendermatched with the MG patients.
Collagen XIII autoantibodies were screened by a modified enzyme-linked immunoassay (ELISA) protocol. Recombinant collagen XIII ectodomain, 15 0.2 mg/ml in Tris-buffered saline (TBS), was coated onto 96-well MaxiSorp plates (Thermo Fisher Scientific, Waltham, Massachusetts) at 4 8C overnight. Thereafter, the plates were blocked with 5% fat-free milk in TBS at room temperature for 3 hours. After removing the blocking solution, human serum pre-diluted 1:10 in the blocking solution was incubated with the coated protein at 4 8C overnight. Horseradish peroxidase (HRP)-conjugated anti-human immunoglobulin G (IgG; Jackson ImmunoResearch, West Grove, Pennsylvania) and its chromogenic substrate, TMB X-tra (KemEn-Tec Diagnostics, Taastrup, Denmark), were used for detection at 450 nm with a multimode microplate reader (Infinite M1000 PRO; Tecan, M€ andorf, Switzerland). Different batches of testing were normalized with a collagen XIII monoclonal antibody. 15 The data were analyzed with GraphPad Prism version 7.02 (GraphPad, Inc., La Jolla, California).
All ELISA-positive sera (ColXIII 1 ) and a few of the negatives and controls were studied further with a cell-based assay and Western blotting. Sera diluted 1:50 in TBS containing 0.01% Tween-20 (TBS-T) and 5% fat-free milk were incubated in protein A/ G-coated plates (Thermo Fisher Scientific) at 4 8C overnight. Conditional media from Chinese hamster ovary (CHO) cells stably expressing collagen XIII tagged with enhanced green fluorescence protein (EGFP) 14 were then incubated with the protein A/G-captured serum IgG proteins at 37 8C for 1 hour. Cells expressing EGFP were used as negative controls. The collagen XIII-EGFP captured on the plates was quantified by green fluorescence detection with the Infinite M1000 PRO (Tecan) device. The data were analyzed using GraphPad Prism ImmunoResearch) and Western Bright electrochemiluminescence reagents (Advansta, Menlo Park, California). Digital imaging was then performed (LAS-3000; GE Life Sciences, Marlborough, Massachusetts). CHO cells overexpressing collagen XIII-EGFP were used for immunofluorescence staining. Cells cultured in Dulbecco's modified Eagle medium (DMEM; Sigma Co., St. Louis, Missouri) supplemented with 10% fetal bovine serum (Biowest, Logan, Utah) were fixed with methanol at -20 8C for 10 min and blocked with 5% milk/PBS for 2 hours followed by 2% donkey serum/PBS for 1 hour. Human sera were diluted 1:10 in 2% donkey serum and incubated with the specimens at 4 8C overnight. Goat anti-human Fab (Jackson ImmunoResearch) and Alexa Fluor 568-conjugated donkey anti-goat IgG (Thermo Fisher Scientific) were used subsequently for immunofluorescence detection. The cell nuclei were stained with Hoechst 33342 (Thermo Fisher Scientific). Specimens were imaged with a confocal microscope (FluoView FV1000; Olympus, Tokyo, Japan) using a 60 3 objective. Figure  1A . By using the cut-off from the mean of controls 1 3 3 standard deviation (SD), 5 patients (all women), but none of the 61 controls, were seropositive for collagen XIII antibody (Fig. 1A and Table 1 ). The average age at MG onset of the 5 positive patients was 25 years and was 45 years for those who were 65 ELISA negative. Four of the 5 patients had been thymectomized, all showing microscopically thymic hyperplasia. Four of them had HLA-B8 antigen. Three of them were AChR antibody seronegative and 2 had low levels of AChR antibody. Four patients had generalized MG and 1 had mainly ocular symptoms. One woman had had severe MG, including swallowing difficulty and dyspnea. None had immunomodulating treatments. In the whole cohort of patients, 7.1% (5 of 70) were collagen XIII antibody seropositive, and 2.9% (2 of 70) were double positive for AChR antibodies and collagen XIII antibodies. Conversely, 15.8% (3 of 19) of patients who were AChR antibody seronegative in this series were collagen XIII antibody seropositive. There were no differences in phenotype of the myasthenics who were collagen XIII antibody seropositive compared with those who were AChR antibody seropositive only or double seronegative.
RESULTS

ELISA screening of collagen XIII antibody in MG patients and controls is summarized in
To study the specificity of the autoantibodies to collagen XIII, we next tested the sera with collagen XIII-EGFP shed in the conditional CHO cell medium. All 5 collagen XIII antibody-positive sera were able to capture collagen XIII-EGFP, showing a band at 100 kDa in Western blotting (Fig. 1B) . One sample with a lower titer (between mean 1 2 3 SD and mean 1 3 3 SD) also showed affinity to collagen XIII. No visible bands were detected from the control and 1 sample that was collagen XIII antibody seronegative (Fig. 1B) .
Immunofluorescence staining showed that the collagen XIII autoantibodies in the MG patient sera (ColXIII 1 /AChR -and ColXIII
) recognized mostly the mature collagen XIII located on the cell membrane and in the ECM ( Fig. 2A  and C) . The control (ColXIII -/AChR -) did not detect collagen XIII in the staining (Fig. 2B) . The sample that was collagen XIII antibody seronegative but AChR antibody seropositive (ColXIII -/ AChR 1 ) showed some non-specific signals localized mostly inside the cells, but the mature collagen XIII in the ECM was not stained (Fig. 2D) .
DISCUSSION
Collagen XIII has been detected in various human and mouse tissues but with generally low expression levels. [19] [20] [21] [22] [23] [24] Early studies reported collagen XIII autoantibodies in patients with thyroidassociated ophthalmopathy, in whom autoantibodies target orbital fat, extraocular muscles, and/or connective tissues. [25] [26] [27] The present data provide information highly relevant in view of the reported occurrence and functional significance of collagen XIII in mouse models and human CMS. 16, 17 In addition, our recent studies suggested that collagen XIII is located at the functional unit of the NMJ, binds acetylcholinesterase-associated collagen (ColQ), and contributes to the distribution pattern of acetylcholine esterase at the NMJ. 28 Therefore, we speculate that a putative pathogenic mechanism of collagen XIII autoantibodies may be hindering the interaction between collagen XIII and other synaptic basal lamina components and, consequently, destabilizing the neuromuscular synapse.
Collagens have a tendency to aggregate and show ambiguous avidity. 15, 29 To avoid false positive results, the ELISA conditions were optimized by reducing the amount of collagen XIII used for coating and improving the blocking efficiency. Due to the low amount of coating protein the detection signal was relatively low, which may cause false negatives. We noticed that a serum under the ELISA cut-off was positive in a cell-based assay with protein A/G-coated plates combined with Western blotting.
MG patients may develop other autoimmune diseases such as systemic lupus erythematosus, Sj€ ogren's syndrome, thyroiditis, or multiple sclerosis. 30 Earlier reports indicated that autoantibodies against collagen XIII were detected in patients affected by thyroid-associated ophthalmopathy. [25] [26] [27] Based on those studies, one would suspect that collagen XIII antibodies are related to multiple autoimmune diseases or linked to ocular symptoms. In the present study, only 1 patient with collagen XIII antibody seropositivity had mainly ocular MG. Studies with a larger number of patient samples are needed to draw further conclusions.
In this study we have demonstrated that collagen XIII is a putative antigen in MG patients. Future studies should consider measuring collagen XIII autoantibodies with a larger number of samples from patients with MG, other autoimmune and neurological diseases, and concomitant testing of MuSK, LRP4, agrin, titin, and RyR autoantibodies, to allow for identification of patient groups with distinct combinations of autoantibodies. In addition, follow-up studies should be performed for the patients who are collagen XIII antibody seropositive vs seronegative, in order to clarify whether the presence of the autoantibodies is correlated with immune system malfunction or with structural muscle damage.
